248 related articles for article (PubMed ID: 30346831)
1. Predicting Responders to Reslizumab after 16 Weeks of Treatment Using an Algorithm Derived from Clinical Studies of Patients with Severe Eosinophilic Asthma.
Bateman ED; Djukanović R; Castro M; Canvin J; Germinaro M; Noble R; Garin M; Buhl R
Am J Respir Crit Care Med; 2019 Feb; 199(4):489-495. PubMed ID: 30346831
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β
Han S; Kim S; Kim H; Suh HS
Curr Med Res Opin; 2019 Sep; 35(9):1597-1605. PubMed ID: 30964365
[No Abstract] [Full Text] [Related]
3. Effect of intravenously administered reslizumab on spirometric lung age in patients with moderate-to-severe eosinophilic asthma.
Carr WW; McDonald M; Meizlik P
Allergy Asthma Proc; 2019 Jul; 40(4):240-249. PubMed ID: 31262379
[No Abstract] [Full Text] [Related]
4. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Weinstein SF; Katial RK; Bardin P; Korn S; McDonald M; Garin M; Bateman ED; Hoyte FCL; Germinaro M
J Allergy Clin Immunol Pract; 2019 Feb; 7(2):589-596.e3. PubMed ID: 30193936
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes and Health-Care Resource Use Associated With Reslizumab Treatment in Adults With Severe Eosinophilic Asthma in Real-World Practice.
Wechsler ME; Peters SP; Hill TD; Ariely R; DePietro MR; Driessen MT; Terasawa EL; Thomason DR; Panettieri RA
Chest; 2021 May; 159(5):1734-1746. PubMed ID: 33333058
[TBL] [Abstract][Full Text] [Related]
6. Reslizumab in Eosinophilic Asthma: A Review.
Deeks ED; Brusselle G
Drugs; 2017 May; 77(7):777-784. PubMed ID: 28421429
[TBL] [Abstract][Full Text] [Related]
7. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
[TBL] [Abstract][Full Text] [Related]
8. Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts.
Corren J; Weinstein S; Janka L; Zangrilli J; Garin M
Chest; 2016 Oct; 150(4):799-810. PubMed ID: 27018175
[TBL] [Abstract][Full Text] [Related]
9. A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma.
Lam J; Hay JW; Salcedo J; Kenyon NJ
J Asthma; 2019 Aug; 56(8):872-881. PubMed ID: 30003833
[No Abstract] [Full Text] [Related]
10. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils.
Brusselle G; Germinaro M; Weiss S; Zangrilli J
Pulm Pharmacol Ther; 2017 Apr; 43():39-45. PubMed ID: 28159511
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma.
Lim HF; Nair P
Expert Rev Respir Med; 2015 Apr; 9(2):135-42. PubMed ID: 25578680
[TBL] [Abstract][Full Text] [Related]
12. Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma.
Murphy K; Jacobs J; Bjermer L; Fahrenholz JM; Shalit Y; Garin M; Zangrilli J; Castro M
J Allergy Clin Immunol Pract; 2017; 5(6):1572-1581.e3. PubMed ID: 29122156
[TBL] [Abstract][Full Text] [Related]
13. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.
Bjermer L; Lemiere C; Maspero J; Weiss S; Zangrilli J; Germinaro M
Chest; 2016 Oct; 150(4):789-798. PubMed ID: 27056586
[TBL] [Abstract][Full Text] [Related]
14. Reslizumab in the treatment of severe eosinophilic asthma: an update.
Walsh GM
Immunotherapy; 2018 Jun; 10(8):695-698. PubMed ID: 29554826
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Reslizumab Treatment in Exacerbation-Prone Patients with Severe Eosinophilic Asthma.
Wechsler ME; Hickey L; Garin M; Chauhan A
J Allergy Clin Immunol Pract; 2020; 8(10):3434-3442.e4. PubMed ID: 32562877
[TBL] [Abstract][Full Text] [Related]
16. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study.
Castro M; Mathur S; Hargreave F; Boulet LP; Xie F; Young J; Wilkins HJ; Henkel T; Nair P;
Am J Respir Crit Care Med; 2011 Nov; 184(10):1125-32. PubMed ID: 21852542
[TBL] [Abstract][Full Text] [Related]
17. [Clinical and economic analysis of Reslizumab use in the treatment of patients with severe allergic eosinophilic asthma].
Kolbin AS; Avdeev SN; Zhuravleva MV; Gomon YM; Balykina YE; Matveyev NV; Proskurin MA; Fedosenko SV
Ter Arkh; 2019 Dec; 91(12):47-56. PubMed ID: 32598589
[TBL] [Abstract][Full Text] [Related]
18. Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma.
Kavanagh JE; Hearn AP; Dhariwal J; d'Ancona G; Douiri A; Roxas C; Fernandes M; Green L; Thomson L; Nanzer AM; Kent BD; Jackson DJ
Chest; 2021 Feb; 159(2):496-506. PubMed ID: 32882249
[TBL] [Abstract][Full Text] [Related]
19. Real-World Effectiveness of Reslizumab in Patients With Severe Eosinophilic Asthma - First Initiators and Switchers.
Hashimoto S; Kroes JA; Eger KA; Mau Asam PF; Hofstee HB; Bendien SA; Braunstahl GJ; Broeders MEAC; Imming LM; Langeveld B; Maitland-van der Zee AH; Oud KTM; Patberg KW; Smeenk FWJM; Romme EAPM; van Bezouw MJ; van de Ven MJ; van Veen A; van Velzen E; van Veen IHPAA; Weersink EJM; Ten Brinke A; Sont JK; Bel EH;
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2099-2108.e6. PubMed ID: 35487369
[TBL] [Abstract][Full Text] [Related]
20. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
Am J Respir Crit Care Med; 2018 Jan; 197(1):38-46. PubMed ID: 28915080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]